NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free REPL Stock Alerts $8.17 -0.08 (-0.97%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$8.04▼$8.4650-Day Range$6.87▼$9.0352-Week Range$5.89▼$24.81Volume1.10 million shsAverage Volume1.47 million shsMarket Capitalization$501.56 millionP/E RatioN/ADividend YieldN/APrice Target$39.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Replimune Group alerts: Email Address Replimune Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside380.4% Upside$39.25 Price TargetShort InterestBearish15.46% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.54Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.28) to ($2.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.45 out of 5 starsMedical Sector132nd out of 938 stocksBiological Products, Except Diagnostic Industry16th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.25, Replimune Group has a forecasted upside of 380.4% from its current price of $8.17.Amount of Analyst CoverageReplimune Group has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.46% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Replimune Group has recently increased by 6.79%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 2.5 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Replimune Group this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows6 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have not sold or bought any company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.28) to ($2.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Replimune Group Stock (NASDAQ:REPL)Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesMarch 28, 2024 | bizjournals.comPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealMarch 26, 2024 | marketwatch.comReplimune Names Sushil Patel as CEO in Broader ShakeupMarch 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 26, 2024 | markets.businessinsider.comReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOMarch 26, 2024 | globenewswire.comReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership TransitionsMarch 16, 2024 | finance.yahoo.comREPL Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comREPL Mar 2024 10.000 putMarch 6, 2024 | finance.yahoo.comReplimune to Present at the American Association for Cancer Research Annual Meeting 2024March 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 5, 2024 | finance.yahoo.comReplimune to Present at Three Upcoming Investor ConferencesFebruary 15, 2024 | markets.businessinsider.comPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy TrialsFebruary 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)February 9, 2024 | msn.comReplimune Group Is Worried About This – Should You Be Worried Too?February 8, 2024 | finance.yahoo.comReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateFebruary 8, 2024 | finance.yahoo.comReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash RunwayFebruary 8, 2024 | investing.comReplimune Group Inc (REPL)February 7, 2024 | marketwatch.comDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations ChiefJanuary 23, 2024 | seekingalpha.comReplimune: The Fall Is Justified, As Virus Therapy Fails Again In CancerDecember 28, 2023 | finance.yahoo.comReplimune to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2023 | ca.finance.yahoo.comREPL Feb 2024 30.000 putDecember 8, 2023 | markets.businessinsider.comBalanced Outlook: Replimune’s Setbacks and Potential in Clinical Trials Justify Buy RatingDecember 7, 2023 | finance.yahoo.comAn Intrinsic Calculation For Replimune Group, Inc. (NASDAQ:REPL) Suggests It's 24% UndervaluedDecember 7, 2023 | markets.businessinsider.comOptimistic Buy Rating on Replimune Group Focused on RP1’s Melanoma Treatment Potential and Strategic RealignmentDecember 5, 2023 | msn.comReplimune shares crash as skin cancer candidate fails trialDecember 5, 2023 | msn.comReplimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goalsDecember 5, 2023 | reuters.comReplimune's skin cancer drug fails in mid-stage studyDecember 5, 2023 | markets.businessinsider.comWhat's Going On With Cancer-Focused Replimune Stock Today?See More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today3/28/2024Fiscal Year End3/31/2024Next Earnings (Estimated)5/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees284Year Founded2015Price Target and Rating Average Stock Price Target$39.25 High Stock Price Target$52.00 Low Stock Price Target$13.00 Potential Upside/Downside+377.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-174,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.94% Return on Assets-35.80% Debt Debt-to-Equity Ratio0.16 Current Ratio12.40 Quick Ratio12.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.80 per share Price / Book0.84Miscellaneous Outstanding Shares61,390,000Free Float48,742,000Market Cap$504.63 million OptionableOptionable Beta1.22 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Comp: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer Dr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Comp: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Comp: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Comp: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsOcugenNASDAQ:OCGNTourmaline BioNASDAQ:TRMLCaribou BiosciencesNASDAQ:CRBUiTeos TherapeuticsNASDAQ:ITOSSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 141,654 shares on 3/11/2024Ownership: 4.460%Fcpm Iii Services B.V.Bought 4,866,499 shares on 3/7/2024Ownership: 7.927%Wellington Management Group LLPSold 14,653 shares on 3/5/2024Ownership: 0.402%Fisher Asset Management LLCBought 21,267 shares on 3/5/2024Ownership: 0.127%Goldman Sachs Group Inc.Bought 1,679,553 shares on 3/1/2024Ownership: 3.647%View All Insider TransactionsView All Institutional Transactions REPL Stock Analysis - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price target for 2024? 4 brokers have issued 12 month price objectives for Replimune Group's shares. Their REPL share price targets range from $13.00 to $52.00. On average, they predict the company's stock price to reach $39.25 in the next year. This suggests a possible upside of 380.4% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2024? Replimune Group's stock was trading at $8.43 at the beginning of the year. Since then, REPL shares have decreased by 3.1% and is now trading at $8.17. View the best growth stocks for 2024 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, February, 8th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.12. What ETFs hold Replimune Group's stock? ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO), What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Replimune Group's major shareholders? Replimune Group's stock is owned by a variety of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (9.53%), Price T Rowe Associates Inc. MD (9.53%), Fcpm Iii Services B.V. (7.93%), Vanguard Group Inc. (4.46%), Vanguard Group Inc. (4.46%) and Goldman Sachs Group Inc. (3.65%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:REPL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.